Free Cash Flow

Canada's busiest airport saw modest passenger growth and strong financials in 2025, navigating supply chain woes, labor strife, and shifting travel trends.

Tsakos Energy Navigation reports a 200% Q4 income jump, capitalizing on high tanker rates while investing in a new fleet of LNG and VLCC vessels.

With its key earnings call on March 12, Aemetis's recent tax credit sales and project milestones are weighed against past financial performance.

Brazilian aerospace giant Embraer shatters financial records and builds its largest-ever order book, signaling a robust recovery in global aviation.

After its public debut, BBOT unveils exciting early data from three unique cancer drugs, including a first in pancreatic cancer, backed by a strong cash runway.

The outdoor gear company reports lower 2025 sales and a net loss but achieves adjusted profit and a debt-free balance sheet on its path to transformation.

NextCure accelerates its high-stakes ovarian cancer drug trial, but with cash dwindling, can it reach the finish line before time runs out?

El Pollo Loco is testing five bold new menu items. We dive into the strategy, the competition, and what it means for the fast-casual chicken wars.

As Concentrix sets its Q1 earnings date, investors are watching closely to see if its AI-driven strategy can overcome market headwinds and cautious guidance.

With FDA Breakthrough status for its MASH drug, a new CEO, and a fortified balance sheet, Altimmune is poised to take on serious liver disease and addiction.

Investors eye Moody's CEO Rob Fauber's upcoming speech for insights on AI strategy, M&A forecasts, and navigating an increasingly complex global economy.

With mixed trial results for its obesity drug and rising costs, Skye Bioscience's upcoming 2025 earnings call is a pivotal moment for investors.

Ad-tech giant Teads reports massive revenue growth post-merger, but a $352M impairment and restructuring signal deep integration challenges.

Following key acquisitions, the AI firm pivots to a vertically integrated defense powerhouse, forecasting explosive growth backed by a swelling order backlog.

German defense tech firm RENK Group reports a record €1.37B revenue, fueled by a 24% surge in its defense business amid global geopolitical tensions.

Vermilion Energy boosts its dividend for the fifth straight year, a move backed by strong cash flow and a strategic focus on premium gas markets.

MISTRAS Group reported record Adjusted EBITDA for 2025, signaling a successful shift to profitability over pure growth, and plans major tech investments.

The energy services firm surpassed analyst expectations with strong revenue growth and a key acquisition, but warns of a challenging year ahead.

With a unique entry-blocking drug, Bioxytran targets COVID, flu, and RSV, moving toward a pivotal trial that could redefine antiviral treatment.

For millions with disabilities, a simple ride is a lifeline. One company is turning a logistical nightmare into a path to independence and essential care.